CIPLA
Back to All Ratios
|
CIPLA Last 5 Year EV/Net Sales History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
EV/Net Sales(x) | 4.66 | 3.15 | 3.72 | 3.45 | 2.10 |
What is the latest EV/Net Sales ratio of CIPLA ?
Year | EV/Net Sales |
---|---|
Mar2024 | 4.66 |
Mar2023 | 3.15 |
Mar2022 | 3.72 |
Mar2021 | 3.45 |
Mar2020 | 2.10 |
How is EV/Net Sales of CIPLA Trending?
Years | EV/Net Sales | % Change | |
---|---|---|---|
Mar2024 | 4.66 | 47.94 | |
Mar2023 | 3.15 | -15.32 | |
Mar2022 | 3.72 | 7.83 | |
Mar2021 | 3.45 | 64.29 | |
Mar2020 | 2.1 | - |
Other Financial Ratios of CIPLA
Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Sales/Fixed Asset Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap |
Compare EV/Net Sales ratio of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹118,365.9 Cr | -2.6% | -3.8% | 19.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹426,518.0 Cr | -0.1% | -6.3% | 49.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹158,636.0 Cr | 3.5% | 0.9% | 66.2% | Stock Analytics | |
MANKIND PHARMA | ₹102,273.0 Cr | 0.9% | -3.4% | 37% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,671.4 Cr | -4.1% | -10.8% | 9.5% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,013.6 Cr | -2% | -6.1% | 49.9% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -2.6% |
-3.8% |
19.2% |
SENSEX | -1.9% |
-5% |
17.5% |
You may also like the below Video Courses